Barely Significant
← all phrases

“a slight trend”

4,079 sentences · 4,079 papers · 4,917 search hits before verification · confirmed specimen

Sighted at

p<0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

A 2018 study revealed that 90% of the Chairs of ophthalmology are men but with a slight trend of recent female Chair appointments. 6 Historically, being a PD has been seen as a pathway to leadership within a medical department, whereas being a DMSE has not been seen as a steppingstone to further academic leadership within a department. 7 The purpose of this study is to analyze the data from the AUPO registry to specifically determine the similarities and differences in demographic trends for DMSEs and PDs from 2010 to 2019.
While our 2D random section data suggested only a slight trend towards larger ribbons in type I VHCs ( Figure 1I ), the large volume data enabled more accurate quantification of individual ribbon volumes ( Figures 4E–G ; Supplementary Table S6 ) alongside the number of cluster-associated SVs.
In total CD4+ T-cells isolated from 5 healthy donors, we observed no significant toxicity at 72 or 96 h after treatment with EED226 (up to 20 μM), A-395 (up to 20 μM), or GSK-343 (up to 5 μM), while we observed a minor decrease in viability at 5 μM UNC1999 ( Figure 8 A and 8 B), consistent with toxicity at this dose of UNC1999 in Jurkat cells. We observed no major change in the expression of either CD69 or CD25 in treated cells at 72 ( Figure 8 C) or 96 h ( Figure 8 D), although a slight trend toward activation in 5 μM UNC1999 treated cells was observed which is consistent with the toxicity data.
A slight trend in decreased mental health and functioning problems (most subscales of BASIS-24 and the IFIP question on symptom burden), and in increased recovery and quality of life (ReQoL, MANSA) were experienced in both arms, from 0 to 12 months, but all differences were non-significant.
9 A slight trend of nonlinearity was observed at doses ≤1.0 mg/kg (Figure 3 ), possibly related to target‐mediated clearance at lower etrolizumab serum concentrations. 9 The slight nonlinearity of PK at doses ≤1.0 mg/kg resulted in shorter half‐lives at lower doses (4.8 to 7.4 days at 0.3 to 1 mg/kg) compared with longer half‐lives at higher doses (10.6 to 13.1 days at 3 to 10 mg/kg).